Eli Lilly (LLY)
(Delayed Data from NYSE)
$877.79 USD
-31.53 (-3.47%)
Updated Sep 27, 2024 03:59 PM ET
After-Market: $877.00 -0.79 (-0.09%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth F Momentum F VGM
Revenue - Line of Business Segments | YR Estimate | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|---|
Net Sales: Immunology [$M] |
-- | 3,798 | 3,345 | 3,361 | 2,462 | 1,793 |
Net Sales: Emgality (Galcanezumab... |
-- | 678 | 651 | 577 | 363 | 163 |
Net Sales: Diabetes Total [$M] |
-- | 19,668 | 14,465 | 13,188 | 11,834 | 11,132 |
Net Sales: Neuroscience: Other Ne... |
-- | 227 | 125 | 95 | -- | -- |
Net Sales: Oncology: Retevmo [$M] |
-- | 254 | 192 | 115 | -- | -- |
Net Sales: Oncology: Tyvyt [$M] |
-- | 393 | 293 | 418 | -- | -- |
Net Sales: Diabetes: Other [$M] |
-- | 530 | 497 | -- | -- | -- |
Net Sales: Oncology: Other Oncolo... |
-- | 613 | 424 | -- | -- | -- |
Net Sales: Other - Other - Total ... |
-- | 1,122 | 3,520 | -- | -- | -- |
Net Sales: Diabetes: Mounjaro -To... |
-- | 5,163 | 483 | -- | -- | -- |
Net Sales: Neurosciences [$M] |
-- | 2,879 | 1,546 | 1,899 | 1,831 | 1,723 |
Net Sales: Oncology [$M] [$M] |
-- | 6,658 | 5,666 | 5,741 | 5,319 | 4,614 |
Net Sales: Other pharmaceuticals ... |
-- | 1,122 | 3,520 | 4,130 | 3,093 | 3,057 |
Net Sales: Cialis [$M] [$M] |
-- | 381 | 587 | 718 | 607 | 891 |
Net Sales: Cymbalta [$M] [$M] |
-- | 243 | 283 | 582 | 768 | 725 |
Net Sales: Erbitux [$M] [$M] |
-- | 597 | 567 | 548 | 536 | 543 |
Net Sales: Forteo [$M] [$M] |
-- | 533 | 613 | 802 | 1,046 | 1,405 |
Net sales: Trajenta [$M] |
-- | 387 | 384 | 373 | 359 | 591 |
Net Sales: Trulicity (Dulaglutide... |
-- | 7,133 | 7,440 | 6,472 | 5,068 | 4,128 |
Net Sales: Humalog [$M] [$M] |
-- | 1,663 | 2,061 | 2,453 | 2,626 | 2,821 |
Net Sales: Taltz (Ixekizumab / LY... |
-- | 2,760 | 2,482 | 2,213 | 1,789 | 1,366 |
Net Sales: Alimta [$M] [$M] |
-- | 218 | 928 | 2,061 | 2,330 | 2,116 |
Net Sales: Jardiance (Empaglifloz... |
-- | 2,745 | 2,066 | 1,491 | 1,154 | 944 |
Net Sales: Verzenio- Total [$M] |
-- | 3,863 | 2,484 | 1,350 | 913 | 580 |
Net Sales: Humulin [$M] [$M] |
-- | 852 | 1,019 | 1,223 | 1,260 | 1,290 |
Net Sales: Olumiant/Baricitinib (... |
-- | 923 | 831 | 1,115 | 639 | 427 |
Net Sales: Cyramza (Ramucirumab /... |
-- | 975 | 971 | 1,033 | 1,033 | 925 |
Net Sales: Basaglar (LY2963016 / ... |
-- | 728 | 760 | 893 | 1,124 | 1,113 |
Revenue - Geographic Segments | YR Estimate | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
Net Sales: Cyramza (Ramucirumab /... |
-- | 402 | 351 | 358 | 382 | 335 |
Net Sales: Cyramza (Ramucirumab /... |
-- | 572 | 620 | 675 | 651 | 79 |
Net Sales: Trulicity (Dulaglutide... |
-- | 5,433 | 5,689 | 4,914 | 4 | 3,155 |
Net Sales: Trulicity (Dulaglutide... |
-- | 1,699 | 1,751 | 1,558 | 1 | 232 |
Net Sales: Jardiance (Empaglifloz... |
-- | 1,600 | 1,195 | 807 | 621 | 566 |
Net Sales: Jardiance (Empaglifloz... |
-- | 1,144 | 872 | 684 | 533 | 139 |
Net Sales: Trajenta (Linagliptin)... |
-- | -- | 90 | 82 | 96 | 225 |
Net Sales: Trajenta (Linagliptin)... |
-- | -- | 294 | 290 | 263 | 153 |
Net Sales: Olumiant/Baricitinib (... |
-- | 226 | 148 | 324 | 64 | 42 |
Net Sales: Olumiant/Baricitinib (... |
-- | 697 | 682 | 791 | 49 | 28 |
Net Sales: Taltz (Ixekizumab / LY... |
-- | 1,832 | 1,725 | 1,542 | 1 | 1,017 |
Net Sales: Taltz (Ixekizumab / LY... |
-- | 928 | 757 | 670 | 500 | 64 |
Net Sales: Basaglar (LY2963016 / ... |
-- | 443 | 471 | 588 | 842 | 876 |
Net Sales: Verzenio- US [$M] |
-- | 2,509 | 1,653 | 835 | 618 | 125 |
Net Sales: Emgality (Galcanezumab... |
-- | 482 | 463 | 435 | 618 | 8 |
Net Sales: Emgality (Galcanezumab... |
-- | 196 | 188 | 143 | 37 | 8 |
Net Sales: Verzenio- ROW [$M] |
-- | 1,354 | 830 | 515 | 294 | 125 |
Net Sales: Diabetes- United State... |
-- | 14,781 | 9,911 | 8,719 | -- | -- |
Net Sales: Diabetes- Outside U.S ... |
-- | 4,887 | 4,554 | 4,469 | -- | -- |
Net Sales: Oncology- United State... |
-- | 3,797 | 3,218 | -- | 2,792 | 2,609 |
Net Sales: Oncology- Outside U.S ... |
-- | 2,861 | 2,448 | -- | 2,527 | 2,006 |
Net Sales: Immunology- United Sta... |
-- | 2,058 | 1,893 | 1,882 | 1,372 | 1,059 |
Net Sales: Immunology- Outside U.... |
-- | 1,740 | 1,452 | 1,479 | 1,090 | 734 |
Net Sales: Neuroscience- United S... |
-- | 696 | 612 | 615 | 487 | 357 |
Net Sales: Neuroscience- Outside ... |
-- | 2,183 | 934 | 1,284 | 1,344 | 1,366 |
Net Sales: Other pharmaceuticals:... |
-- | 459 | 2,556 | 547 | 1,668 | 1,169 |
Net Sales: Other pharmaceuticals:... |
-- | 663 | 964 | 781 | 1,424 | 1,888 |
Revenue: Neuroscience: Retevmo: U... |
-- | 175 | 143 | 103 | -- | -- |
Revenue: Neuroscience: Retevmo: O... |
-- | 78 | 49 | 24 | -- | -- |
Net Sales: Oncology: Tyvyt - Outs... |
-- | 393 | 293 | 418 | -- | -- |
Net Sales: Oncology: Erbitux - U.... |
-- | 529 | 500 | 361 | -- | -- |
Net Sales: Oncology: Erbitux - Ou... |
-- | 68 | 66 | 47 | -- | -- |
Net Sales: Oncology: Other Oncolo... |
-- | 34 | 170 | 120 | -- | -- |
Net Sales: Oncology: Other Oncolo... |
-- | 147 | 254 | 211 | -- | -- |
Revenue to unaffiliated customers... |
-- | -- | -- | 7,708 | -- | -- |
Net Sales: Diabetes: Other - U.S.... |
-- | 175 | 158 | -- | -- | -- |
Revenue: Diabetes: Other - Outsid... |
-- | 355 | 339 | -- | -- | -- |
Net Sales: Other: Other -U.S. [$M... |
-- | 459 | 2,556 | -- | -- | -- |
Net Sales: Other: Other -Outside ... |
-- | 663 | 964 | -- | -- | -- |
Net Sales: Diabetes: Mounjaro -U.... |
-- | 4,834 | 367 | -- | -- | -- |
Net Sales: Diabetes: Mounjaro -Ou... |
-- | 329 | 116 | -- | -- | -- |
Net Sales: Other Neuroscience: Ot... |
-- | 134 | 119 | 102 | -- | -- |
Net Sales: Other Neuroscience- Ou... |
-- | 371 | 439 | 208 | -- | -- |
Net Sales: US-Cialis [$M] [$M] |
-- | 26 | 35 | 11 | -- | 232 |
Net Sales: US-Cymbalta [$M] [$M] |
-- | 31 | 34 | 39 | -- | 50 |
Net Sales: US-Humulin [$M] [$M] |
-- | 610 | 730 | 833 | 866 | 880 |
Net Sales: International-Cialis [... |
-- | 678 | 651 | 708 | -- | 659 |
Net Sales: International-Cymbalt... |
-- | -- | 250 | 543 | -- | 676 |
Net Sales: International-Humulin ... |
-- | 242 | 289 | 390 | 393 | 410 |
Geographic Revenue: China [$M] |
-- | 1,540 | 1,453 | 1,661 | 1,117 | 939 |
Geographic Revenue: United States... |
-- | 21,791 | 18,190 | 16,811 | 14,229 | 12,723 |
Geographic Revenue: Europe [$M] |
-- | 6,175 | 4,299 | 4,777 | 4,188 | 3,765 |
Geographic Revenue: Japan [$M] |
-- | 1,673 | 1,747 | 2,367 | 2,583 | 2,548 |
Net Sales: US-Humalog [$M] [$M] |
-- | 863 | 1,192 | 1,321 | 1 | 1,670 |
Net Sales: US-Alimta [$M] [$M] |
-- | 73 | 544 | 1,234 | 1 | 1,220 |
Net Sales: US-Forteo [$M] [$M] |
-- | 336 | 367 | 442 | 510 | 646 |
Geographic Revenue: Other foreign... |
-- | 2,946 | 2,852 | 2,702 | 2,423 | 2,345 |
Net Sales: Basaglar (LY2963016 / ... |
-- | 285 | 290 | 304 | 282 | 65 |
Net Sales: International-Humalog ... |
-- | 800 | 869 | 1,132 | 1 | 1,151 |
Net Sales: International-Alimta [... |
-- | 145 | 384 | 828 | 1 | 896 |
Net Sales: International-Forteo [... |
-- | 198 | 246 | 360 | 536 | 759 |